
Inventiva S.A. (IVA) Stock Forecast & Price Target
Inventiva S.A. (IVA) Analyst Ratings
Bulls say
Inventiva is viewed positively because lanifibranor has already shown a strong Phase 2 histology signal, with about a 19-point placebo-adjusted fibrosis benefit and a 26-point composite benefit in NATIVE, giving NATiV3 a credible foundation even under a more stringent 72-week design. The company’s Phase 3 setup looks statistically robust, as the 1,009-patient F2/F3 trial needs only about a 7-point composite and 9-point fibrosis gap to succeed, while management reported dropout below 30% and the fifth DMC recommended continuing without changes in October 2024. Fundamentally, the oral pan-PPAR mechanism, favorable F3 and diabetic enrichment, and manageable safety profile support a differentiated commercial position in MASH, especially since the company had €166.1M in cash and cash equivalents at June 30, 2026 and expects runway into 2Q2027.
Bears say
Inventiva is facing a fundamentally challenged investment case because its lead asset has already shown mixed efficacy and meaningful tolerability issues, including a missed primary endpoint in FASST and weight gain, edema, anemia, and aminotransferase elevations that can undermine long-term use. The company also faces a difficult competitive backdrop, as Rezdiffra’s benefit is described as modest and indirect while FGF21s may prove more potent, limiting lanifibranor’s differentiation beyond oral dosing. These clinical and commercial risks are compounded by explicit financing risk and the prospect that any R&D, regulatory, or commercial setback could force dilutive funding, weakening shareholder value.
This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Inventiva S.A. (IVA) Forecast
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares